-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Iqpuae4bIuR2SQDUIMob3aRYUkWgwyErTbJ+ppGf9RJep0Ryx6NK+wUcnOcz4xeN 4/D/QJVODa/GBDeQW2IJ5Q== 0001193125-09-023832.txt : 20090210 0001193125-09-023832.hdr.sgml : 20090210 20090210134503 ACCESSION NUMBER: 0001193125-09-023832 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20090210 DATE AS OF CHANGE: 20090210 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: INFINITY PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001113148 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330655706 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-60943 FILM NUMBER: 09584955 BUSINESS ADDRESS: STREET 1: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6174531000 MAIL ADDRESS: STREET 1: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: INFINITY PHARMACEUTICALS, INC./NEW/ DATE OF NAME CHANGE: 20060913 FORMER COMPANY: FORMER CONFORMED NAME: DISCOVERY PARTNERS INTERNATIONAL INC DATE OF NAME CHANGE: 20000428 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320-1799 BUSINESS PHONE: 805-447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE STREET 2: MAIL STOP 27-3-C CITY: THOUSAND OAKS STATE: CA ZIP: 91320-1799 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 SC 13G/A 1 dsc13ga.htm SCHEDULE 13G AMENDMENT NO. 2 Schedule 13G Amendment No. 2

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 13G

(Rule 13d-102)

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b) (c), AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2

(Amendment No. 2)*

 

 

 

 

Infinity Pharmaceuticals, Inc.

(Name of Issuer)

 

 

Common Stock, par value $0.001 per share

(Title of Class of Securities)

 

 

45665G303

(CUSIP Number)

 

 

March 28, 2008

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

¨ Rule 13d-1(c)

x Rule 13d-1(d)

 

 

 

*   The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 45665G303   13G   Page 2 of 5 Pages

 

  1.  

NAMES OF REPORTING PERSONS

 

Amgen Inc.

    
  2.  

CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP (see instructions)

(a)  

(b)  

    
  3.  

SEC USE ONLY

 

    
  4.  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

    

 

NUMBER OF  

SHARES  

BENEFICIALLY  

OWNED BY  

EACH  

REPORTING  

PERSON  

WITH  

 

  

  5.    SOLE VOTING POWER

 

        -0-

 

  6.    SHARED VOTING POWER

 

        -0-

 

  7.    SOLE DISPOSITIVE POWER

 

        -0-

 

  8.    SHARED DISPOSITIVE POWER

 

        -0-

  9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

-0-

    
10.  

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

 

    
11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

-0-%

    
12.  

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

CO

    

CUSIP No. 45665G303   13G   Page 3 of 5 Pages

 

Item 1(a).  

Name of Issuer:

 

Infinity Pharmaceuticals, Inc.

Item 1(b).  

Address of Issuer’s Principal Executive Offices:

 

780 Memorial Drive

Cambridge, MA 02139

Item 2(a).  

Name of Person Filing:

 

Amgen Inc.

Item 2(b).  

Address of Principal Business Office or, if none, Residence:

 

One Amgen Center Drive

Thousand Oaks, CA 91320-1799

Item 2(c).  

Citizenship:

 

Delaware

Item 2(d).  

Title of Class of Securities:

 

Common stock, par value $0.001 per share

Item 2(e).  

CUSIP Number:

 

45665G303

Item 3.   Not applicable.
Item 4.  

Ownership.

 

(a)    Amount beneficially owned: -0-

CUSIP No. 45665G303   13G   Page 4 of 5 Pages

 

 

(b)    Percent of class:

 

(c)    Number of shares as to which such person has:

 

(i)     Sole power to vote or to direct the vote -0-

 

(ii)    Shared power to vote or to direct the vote -0-

 

(iii)  Sole power to dispose or to direct the disposition of -0-

 

(iv)   Shared power to dispose or to direct the disposition of -0-

Item 5.  

Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [X].

Item 6.  

Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable.

Item 7.  

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

 

Not applicable.

Item 8.  

Identification and Classification of Members of the Group.

 

Not applicable.

Item 9.  

Notice of Dissolution of Group.

 

Not applicable.

Item 10.  

Certifications.

 

Not Applicable

CUSIP No. 45665G303   13G   Page 5 of 5 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: February 9, 2009
AMGEN INC.
By:   /s/ David J. Scott
  Name:   David J. Scott
  Title:   Senior Vice President, General Counsel and Secretary
 -----END PRIVACY-ENHANCED MESSAGE-----